Develops and sells RNAi medicines for people with rare and common diseases, and works with pharmaceutical companies to develop and commercialize additional treatments.
10-K for FY2025, filed Feb 12, 2026Alnylam Pharmaceuticals, Inc. (also referred to as Alnylam, the Company, we, our or us) is a global commercial-stage biopharmaceutical…View ↗
We currently have six marketed products, including two products that are commercialized by collaborators, and more than 20 clinical…View ↗
We earn revenue in connection with collaboration agreements that allow our collaborators to utilize our technology platforms and develop…View ↗
Alnylam sells its medicines to healthcare providers, with product sales counted when customers receive the products. It also earns collaboration revenue through agreements that let partners use its technology and develop candidates, and royalties on sales of products commercialized by collaborators.
10-K for FY2025, filed Feb 12, 2026Our net product revenues are recognized, net of variable consideration related to certain allowances and accruals, at the time the customer…View ↗
Chargebacks: We estimate obligations resulting from contractual commitments with the government and other entities to sell products to…View ↗
We earn revenue in connection with collaboration agreements that allow our collaborators to utilize our technology platforms and develop…View ↗
As of December 31, 2025, we generate worldwide product revenues from our four commercialized products, AMVUTTRA, ONPATTRO, GIVLAARI and…View ↗
$3.7B
10-K for FY2025, filed Feb 12, 2026
$3.7B ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Net product revenues
Sold outright
10-K for FY2025, filed Feb 12, 2026 |
80%
FY2022: 86%
|
Net product revenues, FY2025
$3B Sources
|
Sold outright |
|
Net revenues from collaborations
|
15%
FY2022: 13%
|
Net revenues from collaborations, FY2025
$553.4M Sources
|
|
|
Royalty revenue
Licensed
|
4.7%
FY2022: 0.8%
|
Royalty revenue, FY2025
$174M Sources
|
Licensed |
Alnylam sells medicines to qualified healthcare providers, including customers that purchase directly. Novartis commercializes Leqvio and Sanofi commercializes Qfitlia.
10-K for FY2025, filed Feb 12, 2026Chargebacks: We estimate obligations resulting from contractual commitments with the government and other entities to sell products to…View ↗
Leqvio (inclisiran) is being developed and commercialized by our collaborator Novartis AG, or Novartis, and has received marketing…View ↗
Qfitlia (fitusiran) is being commercialized by our collaborator, Genzyme Corporation, a Sanofi Company, or Sanofi, and was approved by the…View ↗
Yes. It kept 8 cents of every revenue dollar as net income in FY2025 and turned 13 cents into free cash flow.
10-Q for Q3 FY2026, filed Oct 29, 2026
$2.2BView ↗
10-Q for Q3 FY2026, filed Oct 29, 2026
Open tableView ↗
8-K, filed Jul 30, 2026
− Revises Full-Year 2026 TTR Net Product Revenue Guidance from $4,400 to $4,700 Million to $4,200 to $4,500 Million (75% Growth Compared…View ↗
Growing. Revenue grew 4.4x in 4 years, from $844.3M in FY2021 to $3.7B in FY2025, about 45% a year.
Broader AMVUTTRA use
The older report described AMVUTTRA as approved for polyneuropathy, with cardiomyopathy still in development; the latest report describes approval for cardiomyopathy too.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 12, 2026AMVUTTRA is approved in the United States, or U.S., for the treatment of hereditary transthyretin-mediated amyloidosis, or hATTR…View ↗
Fitusiran enters commercialization
The older report describes fitusiran as a hemophilia program being advanced by Sanofi; the latest report says Sanofi is commercializing Qfitlia, which has approvals for hemophilia.
10-K for FY2022, filed Feb 23, 2023 10-K for FY2025, filed Feb 12, 2026In addition to our marketed products, we have multiple late-stage investigational programs advancing toward potential commercialization.…View ↗
Qfitlia (fitusiran) is being commercialized by our collaborator, Genzyme Corporation, a Sanofi Company, or Sanofi, and was approved by the…View ↗
Competes with ADARx Pharmaceuticals, Amgen, Argo Biopharmaceutical, Aro Biotherapeutics, Arrowhead Pharmaceuticals, AstraZeneca, Dyne Therapeutics, Eli Lilly, GlaxoSmithKline, Novo Nordisk, SanegeneBio, Sarepta Therapeutics, Silence Therapeutics, Takeda Pharmaceutical, Wave Life Sciences, Ionis, Intellia, Pfizer, BridgeBio Pharma, and Bayer
10-K for FY2025, filed Feb 12, 2026Companies working on chemically synthesized siRNAs include but are not limited to ADARx Pharmaceuticals, Inc., or ADARx, Amgen Inc., Argo…View ↗
Loading...